# DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

> **NCT03716180** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT03716180
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-05
- **Primary completion:** 2020-10-08
- **Final completion:** 2030-09-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03716180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03716180, "DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03716180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*